You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Could Selective Calpain-2 Inhibitors be used for AD Treatment?
Contributor:
Baudry, Michel
Published:
International Assotiation of Biomedical Sciences, 2023
Published in:
International Journal of Biomedical Science, 19 (2023) 4
Language:
Without Specification
DOI:
10.59566/iabs.2023.p036
ISSN:
1550-9702;
1555-2810
Origination:
Footnote:
Description:
Work in our laboratory over the last 10 years has shown that prolonged brain calpain-2 activation following a variety of insults plays a critical role in brain pathology resulting from these insults, including neuronal damage, brain inflammation, and cognitive impairment. My laboratory is collaborating with NeurAegis, Inc, to develop selective calpain-2 inhibitors for the treatment of a number of neurological disorders, including traumatic brain injury and concussions. We have identified a lead clinical candidate, NA-184, which significantly inhibits neuronal damage in rodent models of TBI, as well as a blood biomarker, P13BP, which reflects brain calpain-2 activation. We will discuss our plans to bring NA-184 to the clinic in 2024.